Chang-Song Wang

Dr. Chang-Song Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in Military Medical Research
Verified
Journal Article
Open access
PDF file
FPFei Pei
Fei Pei
RYRen-Qi Yao
Ren-Qi Yao
CRChao Ren
Chao Ren
SBSoheyl Bahrami
Soheyl Bahrami
Timothy R. BilliarTimothy R. Billiar
Timothy R. Billiar
YYYong-ming Yao
Yong-ming Yao
Emerged evidence has indicated that immunosuppression is involved in the occurrence and development of sepsis. To provide clinical practice recommendations on the immune function in sepsis, an expert consensus focusing on the monitoring and treatment of sepsis-induced immunosuppression was developed. Literature related to the immune monitoring and treatment of sepsis were retrieved from PubMed, Web of Science, and Chinese National Knowledge Infrastructure to design items and expert opinions were collected through an online questionnaire. Then, the Delphi method was used to form consensus opinions, and RAND appropriateness method was developed to provide consistency evaluation and recommendation levels for consensus opinions. This consensus achieved satisfactory results through two rounds of questionnaire survey, with 2 statements rated as perfect consistency, 13 as very good consistency, and 9 as good consistency. After summarizing the results, a total of 14 strong recommended opinions, 8 weak recommended opinions and 2 non-recommended opinions were produced. Finally, a face-to-face discussion of the consensus opinions was performed through an online meeting, and all judges unanimously agreed on the content of this consensus. In summary, this expert consensus provides a preliminary guidance for the monitoring and treatment of immunosuppression in patients with sepsis.

24 February 2026 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
DWDawei Wang
Dawei Wang
YZYuxin Zhou
Yuxin Zhou
HLHongxu Li
Hongxu Li
YXYu Xin
Yu Xin
MYMengyao Yuan
Mengyao Yuan
CWChang-Song Wang
Chang-Song Wang
Immune checkpoint inhibitors (ICIs) activate the immune system by blocking PD-1, CTLA-4, and PD-L1, thereby inducing autoimmune-mediated adverse reactions known as immune-related adverse events (irAEs). When two or more organs are involved, this condition is defined as multi-organ immune-related adverse events (multi-organ irAEs). Patients with multi-organ irAEs account for approximately 20%–30% of all irAE cases; however, clinical research focusing on this subset remains limited. The purpose of this study is to analyze the clinical characteristics, optimal therapeutic approaches, and mortality-related risk factors of multi-organ irAEs. We searched all case reports of irAEs associated with ICIs in the PubMed, Web of Science, Cochrane Library, and Embase databases from their inception to January 2022. Search terms included “Immune Checkpoint Inhibitors”, “Checkpoint Inhibitors, Immune”, “Immune Checkpoint Blockers”, “PD-L1”, “CTLA-4 Inhibitor”, “PD-1”, and “Case report”. After removing duplicate literature and applying strict inclusion/exclusion criteria, a total of 2,740 articles were included, encompassing 2,964 patients (782 with multi-organ irAEs and 2,182 with single-organ irAEs). Patients were stratified by the number of affected organs to compare clinical characteristics between multi-organ and single-organ irAE groups. For patients with multi-organ irAEs, subgroup analyzes were performed based on glucocorticoid dosage to identify optimal treatment strategies, and further stratified by survival status to explore potential mortality risk factors. No statistically significant differences in age or sex were observed between patients with multi-organ irAEs and those with single-organ irAEs (P > 0.05). However, the multi-organ irAE group exhibited significantly higher proportions of cardiovascular toxicity, thyroid toxicity, skin toxicity, and severe adverse reactions (P < 0.05), as well as a significantly elevated mortality rate (P < 0.05). Among patients with severe multi-organ irAEs, there were no significant differences in sex or age between high-dose and low-dose glucocorticoid subgroups (P > 0.05); notably, the high-dose glucocorticoid group had a significantly higher mortality rate (P < 0.05). For patients with non-severe multi-organ irAEs, no statistically significant differences in sex, age, mortality, or prognosis were detected between high-dose and low-dose glucocorticoid groups (P > 0.05). Multivariate logistic regression analysis revealed that cardiovascular toxicity, pulmonary toxicity, hepatotoxicity, and myositis were positively correlated with mortality in patients with multi-organ irAEs (OR > 1, P < 0.05). The most common organ combinations in multi-organ irAEs are “cardiac + neurological, cardiac + pulmonary, thyroid + pituitary, cardiac + hepatic, and gastrointestinal + skin”. Multi-organ irAEs are generally more severe and associated with poorer outcomes compared to single-organ irAEs. High-dose glucocorticoids did not demonstrate superior prognostic outcomes and may be associated with an increased mortality risk in severe irAEs.clinical decisions regarding glucocorticoid dosing should be individualized based on the severity of irAEs and the specific organs involved.Cardiovascular toxicity, pulmonary toxicity, hepatotoxicity, and myositis are potential mortality risk factors for multi-organ irAEs induced by ICIs.

10 April 2025 in Immunology
Verified
Journal Article
Closed access
MYMengyao Yuan
Mengyao Yuan
PHPengfei Huang
Pengfei Huang
YLYuhan Liu
Yuhan Liu
LSLifeng Shen
Lifeng Shen
CNChuanchuan Nan
Chuanchuan Nan
CWChang-Song Wang
Chang-Song Wang

1 October 2024 in Intensive Care Medicine Experimental
Verified
Journal Article
Open access
PDF file
LLLinqiong Liu
Linqiong Liu
YLYuxi Liu
Yuxi Liu
YXYu Xin
Yu Xin
YLYanqi Liu
Yanqi Liu
YGYan Gao
Yan Gao
CWChang-Song Wang
Chang-Song Wang
Background: Polymyxins have been revived as a last-line therapeutic option for multi-drug resistant bacteria and continue to account for a significant proportion of global antibiotic usage. However, kidney injury is often a treatment limiting event with kidney failure rates ranging from 5 to 13%. The mechanisms underlying polymyxin-induced nephrotoxicity are currently unclear. Researches of polymyxin-associated acute kidney injury (AKI) models need to be more standardized, which is crucial for obtaining consistent and robust mechanistic results. Methods: In this study, male C57BL/6 mice received different doses of polymyxin B (PB) and polymyxin E (PE, also known as colistin) by different routes once daily (QD), twice daily (BID), and thrice daily (TID) for 3 days. We continuously monitored the glomerular filtration rate (GFR) and the AKI biomarkers, including serum creatinine (Scr), blood urea nitrogen (BUN), neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1). We also performed histopathological examinations to assess the extent of kidney injury. Results: Mice receiving PB (35 mg/kg/day subcutaneously) once daily exhibited a significant decrease in GFR and a notable increase in KIM-1 two hours after the first dose. Changes in GFR and KIM-1 at 24, 48 and 72 h were consistent and demonstrated the occurrence of kidney injury. Histopathological assessments showed a positive correlation between the severity of kidney injury and the changes in GFR and KIM-1 (Spearman’s rho = 0.3167, P = 0.0264). The other groups of mice injected with PB and PE did not show significant changes in GFR and AKI biomarkers compared to the control group. Conclusion: The group receiving PB (35 mg/kg/day subcutaneously) once daily consistently developed AKI at 2 h after the first dose. Establishing an early and stable AKI model facilitates researches into the mechanisms of early-stage kidney injury. In addition, our results indicated that PE had less toxicity than PB and mice receiving the same dose of PB in the QD group exhibited more severe kidney injury than the BID and TID groups.

26 August 2025 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
XWXibo Wang
Xibo Wang
PHPengfei Huang
Pengfei Huang
YLYinghao Luo
Yinghao Luo
YXYu Xin
Yu Xin
YLYue Li
Yue Li
KYKai-jiang Yu
Kai-jiang Yu
Sepsis-associated acute kidney injury (SA-AKI) is strongly associated with increased mortality in critical patients. The early detection of SA-AKI is crucial for clinical intervention. This study aims to integrate multiple metabolomics data related to SA-AKI to identify and validate novel metabolic markers. Real-time glomerular filtration rate (RT-GFR) measurement was adopted to establish SA-AKI mice. Untargeted metabolomics sequencing was performed on SA-AKI mice renal tissue (Control—LPS-8 h—LPS-24 h, N = 4) and urine samples (Control group vs. LPS-24 h group, N = 6). Time series analysis and random forest algorithm were employed to identify key metabolic molecule. Subsequently, renal spatiotemporal metabolomics was used to explore the specific distribution of key molecule. Eventually, a clinical cohort (20 healthy volunteers vs. 30 sepsis patients vs. 45 SA-AKI patients) urine quantitative metabolomic analysis was carried out to validate it as a biomarker and construct a diagnostic model via logistic regression (LR). Forty-two key renal metabolites and top fifty urinary metabolites were determined through multidimensional metabolomics study of SA-AKI mice. Urinary 3-Methylhistidine (3-MH) was charactered as a potential biomarker. The distribution of 3-MH increased in collecting ducts through renal spatiotemporal metabolomics sequencing. Then, we recruited 95 urine samples to validate its diagnostic performance (AUC = 0.86, 95% CI 0.77–0.95) and its role as an independent predictive factor for SA-AKI (OR = 0.21, 95% CI: 0.05–0.84, p < 0.05). Ultimately, a diagnostic model combined urinary 3-MH with clinical variables was constructed to identify SA-AKI (AUC = 0.89, 95% CI 0.74–1.00). We proposed that urinary 3-Methylhistidine has potential diagnostic value for SA-AKI screening. Future studies will focus on its performance in other clinical populations to comprehensively evaluate its diagnostic role.

16 July 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
YJYingnan Ju
Yingnan Ju
KLKunbin Liu
Kunbin Liu
YXYu Xiao
Yu Xiao
GMGang Ma
Gang Ma
BZBiao Zhu
Biao Zhu
DWDonghao Wang
Donghao Wang
Background: Infection is a common and often fatal complication in cancer patients. Notably, cancer patients account for up to 21% of all sepsis cases. Furthermore, sepsis is present in 30% of all deaths among those hospitalized with cancer. However, comprehensive antimicrobial resistance (AMR) surveillance data specific to this population are lacking. This gap hinders the effectiveness of antimicrobial stewardship programs (ASPs). Methods: We investigated bacterial distribution and AMR patterns in Chinese cancer patients to inform empirical therapy and ASPs. This multicenter retrospective study collected hospital-wide clinical isolates and drug-susceptibility data from 23 cancer centers during 2016–2023. All procedures followed standardized methods in accordance with national surveillance protocols and Clinical and Laboratory Standards Institute guidelines. Data were subjected to dual validation using WHONET and a domestically developed big-data system. Results: Gram-negative 75.4% (270,609), Gram-positive 24.6% (88,177) of 358,786 isolates from cancer patients in these oncology centers. Predominant Gram-negative species were Klebsiella pneumoniae , Escherichia coli , Pseudomonas aeruginosa , Acinetobacter baumannii , and Enterobacter cloacae . Escherichia coli exhibited low imipenem resistance (0.9–1.5%) with a recent increase (2021–2023: APC = 16.57%, p < 0.001). Klebsiella pneumoniae showed stable imipenem resistance (1.6–1.9%) but increasing meropenem resistance (0.4–1.6%). Pseudomonas aeruginosa imipenem resistance declined (12.5–7.9%), while meropenem resistance remained stable (7.0–5.2%); while Acinetobacter baumannii carbapenem resistance increased substantially (imipenem: 9.6–18.4%; meropenem: 4.7–18.8%). Leading Gram-positive organisms were Staphylococcus epidermidis , Staphylococcus aureus , Enterococcus faecium , Enterococcus faecalis , and Staphylococcus haemolyticus . Methicillin-resistant Staphylococcus aureus (MRSA) resistance declined over five years, with no resistance to linezolid, vancomycin, or teicoplanin. Enterococcus spp. gradually developed resistance to last-resort antibiotics. Conclusion: Carbapenem resistance among common Gram-negatives in cancer patients was below national averages. MRSA and enterococcal resistance were also below national levels. These findings underscore the unique resistance epidemiology in oncology, supporting tailored guidelines and dedicated surveillance.